Aguilera D, Coupry A, Holzapfel L, Karlin P, Carrère-Debat D, Giudicelli D P, Gontier D
Pathol Biol (Paris). 1986 Jun;34(5 Pt 2):657-62.
Respiratory tract infections in intensive care units have a high fatality rate, perhaps as a result of the poor diffusion into bronchial secretions of aminoglucosides given by a systemic route. Endotracheal administration of aminoglycosides has been advocated but the optimal dosage remains to be determined. To investigate this problem we studied 13 patients free of renal failure and 6 patients with renal failure. Netilmicin was given by continuous endotracheal infusion in a daily dosage of 3 to 30 mg/kg. A good correlation was found between infused doses and serum concentrations; very high bronchial secretion concentrations were consistently found. There is a significant risk of accumulation in patients with renal failure. The characteristics of the respiratory tract secretions had no influence on the passage of netilmicin into the bloodstream. The dosages we advocate on the basis of our results are 8 mg/kg/day in patients free of renal failure and 4 mg/kg/day in patients with renal failure; serum netilmicin concentrations should not exceed 1 microgram/ml.
重症监护病房中的呼吸道感染病死率很高,这可能是由于全身给药时氨基糖苷类药物在支气管分泌物中的扩散不佳所致。有人主张气管内给予氨基糖苷类药物,但最佳剂量仍有待确定。为了研究这个问题,我们对13例无肾衰竭患者和6例肾衰竭患者进行了研究。奈替米星通过气管内持续输注给药,日剂量为3至30mg/kg。发现输注剂量与血清浓度之间有良好的相关性;始终发现支气管分泌物浓度非常高。肾衰竭患者有明显的蓄积风险。呼吸道分泌物的特性对奈替米星进入血液没有影响。根据我们的研究结果,我们主张的剂量是无肾衰竭患者为8mg/kg/天,肾衰竭患者为4mg/kg/天;血清奈替米星浓度不应超过1μg/ml。